Zynerba Pharma to start Phase 1 study of ZYN001 in first half of next year; top-line data from mid-stage study of ZYN002 expected in same time frame; shares off 3%

• Thinly traded nano cap Zynerba Pharmaceuticals (NASDAQ:ZYNE -2.7%) eases on light volume in early trading. The company updated investors this morning on the status on its top product candidates.
• ZYN001, a prodrug of THC formulated in a transdermal patch under development for the treatment of fibromyalgia and peripheral neuropathic pain, will enter Phase 1 development in H1 2017 with Phase 2 studies to follow in H2 2017.
• Top-line results from three Phase 2 studies of ZYN002, a synthetic cannabidiol formulated as a topical gel, remain on track for H1 2017. Two are ongoing, in refractory epilepsy and osteoarthritis of the knee while a third, in Fragile X Syndrome, should commence this quarter.